Federal Appeals Court Rejects E-Cigarette Marketing Challenge Again.

Aug.31.2022
Federal Appeals Court Rejects E-Cigarette Marketing Challenge Again.
Federal appeals court rejects request to review FDA ban on marketing e-cigarettes, marking the seventh such loss for manufacturers.

In four separate rulings, the Federal Appeals Court has once again rejected requests from electronic cigarette manufacturers to review the FDA's marketing rejection orders (MDO). Seven companies have now lost their challenges in the circuit courts, while six have emerged victorious.


A three-judge panel in the Seventh Circuit Court of Appeals unanimously ruled against Gripum LLC, an Illinois-based company producing bottled e-cigarette liquid under several brands, and upheld the decision of the FDA.


The company known as Gripum, also referred to as the OPMH project, submitted a pre-market tobacco application (PMTA) in September 2020 for approximately 200 bottled e-liquid products with non-tobacco flavors. The application was received by the FDA's Center for Tobacco Products in September. On August 8th, 2021, Gripum submitted a letter of intent for review and was granted a delay on FDA enforcement in November of the same year. On April 20th of this year, the company participated in an oral argument in court.


Gripum alleges that the FDA's refusal to allow marketing is arbitrary and capricious, as neither Congress (in the Tobacco Control Act) nor the agency (in its guidance documents) have "established any necessary, discernible standards" to determine whether Gripum's products are "appropriate for the protection of public health." The company also argues that the FDA changed the evidence standard for PMTAs after the application deadline had passed and failed to conduct personalized PMTA reviews as required by the Tobacco Control Act.


The Federal Appeals Court still faces multiple challenges on other issues, as well as unresolved internal appeals within the FDA.


The court rejected all three arguments presented by Gripum, stating that the FDA's "method of decision-making was both reasonable and in accordance with the Tobacco Control Act.


Two electronic cigarette manufacturers, Triton Distribution and Vaptasia of the Fifth Circuit Court of Appeals, as well as four companies from Washington, D.C., had previously failed in similar reasoning during two rounds of appeals. However, last week, six small electronic cigarette companies won support for their appeal against the FDA's decision from the Eleventh Circuit Court of Appeals.


Several federal appellate courts still have multiple challenges, and there are unresolved internal appeals within the FDA.


Two of the three judges who opposed Gripum were nominated to the court by the Democratic president, while the third was nominated by a Republican. The headquarters of the Seventh Circuit Court is located in Chicago and covers appeals from Illinois, Indiana, and Wisconsin.


Gripum can now seek an en banc review of the case (a full rehearing by the Seventh Circuit Court of Appeals). Triton and Vaptasia are seeking this option in the Fifth Circuit Court of Appeals.


Statement:


This article is compiled from third-party information and is intended solely for industry communication and learning.


This article does not represent the views of 2FIRSTS and 2FIRSTS cannot confirm the authenticity or accuracy of the article's content. The translation of this article is only intended for industry exchange and research purposes.


Due to limitations in translation ability, the translated article may not fully reflect the original text. Please refer to the original text for accuracy.


2FIRSTS aligns completely with the Chinese government regarding any domestic, Hong Kong, Macau, Taiwan, or foreign-related statements and positions.


The copyright of the compiled information belongs to the original media and author. If there are any violations, please contact us for removal.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

UK Launches Call for Evidence to Shape New Tobacco and Vapes Regulations
UK Launches Call for Evidence to Shape New Tobacco and Vapes Regulations
The UK's Department of Health and Social Care (DHSC) has launched an eight-week comprehensive call for evidence to inform new regulations under the forthcoming Tobacco and Vapes Bill, with a deadline of December 3, 2025. The initiative aims to systematically gather evidence on vape flavors, ingredients, nicotine levels, and product design, as well as proposals for an omnichannel retail licensing scheme for tobacco and vapes and a new product registration system.
Nov.04 by 2FIRSTS.ai
Japan Tobacco launches limited-edition Ploom AURA color “Bronze Royal,” priced at about $27
Japan Tobacco launches limited-edition Ploom AURA color “Bronze Royal,” priced at about $27
Japan Tobacco (JT) announced that Ploom AURA has added a second limited-edition colorway, “Bronze Royal,” which will be available in limited quantities through official channels starting November 11, priced at approximately $27.3.
Nov.12 by 2FIRSTS.ai
Jinjia Venture Faces New Judicial Auction, Control Unchanged
Jinjia Venture Faces New Judicial Auction, Control Unchanged
Jinjia Group said its controlling shareholder, Jinjia Venture, will have part of its holdings auctioned by the Shenzhen Nanshan Court, involving 43.4 million shares. Earlier, the Shenzhen Intermediate Court announced another auction of 37.27 million shares. Together they represent 5.56% of total equity. Jinjia said the auctions will not affect company control.
Oct.23 by 2FIRSTS.ai
U.S. FDA Includes Cytisinicline for Vaping Addiction in National Priority Voucher Program, Shortens Review to 1–2 Months
U.S. FDA Includes Cytisinicline for Vaping Addiction in National Priority Voucher Program, Shortens Review to 1–2 Months
The U.S. Food and Drug Administration (FDA) has added Cytisinicline, a plant-based therapy developed by Achieve Life Sciences for nicotine vaping addiction, to its new National Priority Voucher (CNPV) program. The initiative shortens drug review timelines from 10–12 months to just 1–2 months, expediting approval for treatments that address major public health needs.
Oct.20 by 2FIRSTS.ai
The Spanish Nicotine Pouches Association (ABN) is officially launched, calling for a clear regulatory framework grounded in scientific evidence
The Spanish Nicotine Pouches Association (ABN) is officially launched, calling for a clear regulatory framework grounded in scientific evidence
The Spanish Nicotine Pouches Association (ABN) has launched in Madrid, uniting more than 40 companies to call for science-based, proportionate regulation. The group warns that a proposed 0.99 mg nicotine cap could amount to a de facto ban and introduces new voluntary industry standards in response.
Dec.03
Altria Q3 2025 Earnings Report: Net Revenue of $6.072 Billion and Launch of on!PLUS in the U.S.
Altria Q3 2025 Earnings Report: Net Revenue of $6.072 Billion and Launch of on!PLUS in the U.S.
Altria reported Q3 2025 net revenue of $6.072 billion, a 3.0% year-on-year decline. Adjusted EPS increased 3.6% to $1.45. The company expanded its share repurchase program to $2 billion and launched the on!PLUS nicotine pouch in Florida, North Carolina, and Texas.
Oct.31 by 2FIRSTS.ai